THE TAPESTRY AUTISM STUDY
About Us
Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system. Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disorders and disease pathology, progression, and symptoms.
The company is advancing a pipeline of “microbial-inspired therapeutics™” for conditions with significant unmet patient need, including autism and Parkinson’s disease, and is also pursuing pre-clinical discovery of gut-targeted therapies in oncology.
Axial’s lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.
For more information, visit https://axialtx.com.
Our Mission
At Axial, our mission is to discover and develop targeted small molecule therapeutics to treat serious diseases and conditions by leveraging the microbiome’s role in human health. Our scientific focus on the microbiome gut-brain axis represents a transformative therapeutic approach that has potential to treat neurological diseases and disorders in ways never before possible.
A Potential New Approach to Treating
Autism-Related Irritability
Understanding the Study
The purpose of this study is to learn if the study medication may help improve irritability in 5 to 17-year-old adolescents compared to placebo. AB-2004 was shown to be safe and well tolerated in a previous study involving adolescents with ASD. Eligible participants will be randomly assigned to receive either AB-2004 or placebo.
About the Study Medication
- AB-2004 is an experimental therapy that is being developed as a potential treatment for irritability associated with autism.
- Formulated as a powder, the medication is to be mixed with any soft food your child may like such as yogurt or apple sauce.
- It is taken by mouth 3 times per day and is tasteless and odourless.
If you think your child is eligible for the study take the next step
THe tapestry Autism study
Lets Get Connected
Contact Axial Therapeutics